An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Subcutaneously administered 30 mg icatibant has been shown to be a safe and efficacious treatment in clinical trials. It is the only specific treatment authorized for self-administration by the subcutaneous route offering increased patient independence.